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Abstract 
Background. Patients with chronic kidney disease (CKD) have increased all-cause mortality, 
especially cardiovascular. The majority of patients with CKD have stages 1–3 and are treated 
by primary care physicians and nephrologists. Arterial hypertension (HTN) is highly 
prevalent comorbidity among CKD population, but its control remains poor.  
Material and methods. This retrospective non-interventional cross-sectional study was 
conducted in the Centre of Nephrology Care in Dnipropetrovsk Mechnikov Regional 
Hospital, Dnipro, Ukraine. We aimed to select patients who are supposed to be followed-up 
by primary care practitioners but due to certain reasons required nephrologist’s consultation. 
From 4540 patients who received medical care in the Centre of Nephrology Care 365 patients 
fulfilled inclusion criteria. They were subdivided by presence of HTN, CKD stage, presence 
 of proteinuria and achieving blood pressure targets according to different standards. All 
patients were examined and followed-up according to local and European standards.  
Results. Forty-nine percent of patients had known HTN, and 21% had HTN de novo. 
Advance of CKD stage was significantly associated with increase in the most of laboratory 
findings, age and BP values. Non-proteinuric patients achieved BP goals significantly more 
often, than proteinuric ones. Females achieved BP targets more often, than males. 
Monotherapy was the most common treatment regimen.  
Conclusions. HTN occurs in 70% of patients with CKD and it is controlled in up to 34% of 
cases. HTN is important factor of CKD progression and it is closely connected with GFR and 
proteinuria. 
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Introduction 
Patients with chronic kidney disease (CKD) have increased risk of mortality, cardiovascular 
(CV) disease and development of end-stage renal disease (ESRD) [1]⁠ . The majority of 
patients with CKD have stages 1–3 and are treated by primary care physicians (PCPs) and 
nephrologists [2] ⁠ . Management of patients with early-stages CKD is problematic, because 
there is no sufficient evidence on the expediency of early CKD intervention [2]⁠ . 
Arterial hypertension (HTN) is highly prevalent in CKD population [3] ⁠  and it is the second 
cause of end-stage renal disease worldwide [4] ⁠ . Control of HTN in CKD patients remains 
suboptimal regardless of region and it may be due to various reasons: poorly controlled HTN 
in advanced stages of CKD, low awareness of HTN treatment guidelines in CKD patients, 
inadequate drug or dose choice etc. [2] ⁠ . Importantly, CKD patients are older than in general 
population [5] ⁠  and may require different blood pressure (BP) targets [6] ⁠ . In elderly 
individuals, age-related decline in glomerular filtration rate (GFR) may be difficult to 
differentiate from CKD [7] ⁠ . 
But for the majority of patients with CKD it is still uncertain what BP targets should be 
chosen and what should be taken into consideration before choosing BP target. BP 
management guidelines, provided by International Society of Nephrology (KDIGO) [8] ⁠ , 
 European Society of Cardiology (ESC) [9] and American College of Cardiology (ACC) 
[10]⁠  and issued between 2012th and 2017th tended to get stricter with time and 2017 ACC 
guidelines recommend target BP for patients with CKD to be < 130/80 mm Hg. But despite 
convincing results of SPRINT trial [11] ⁠ , showing benefits of strict BP control in patients 
with CKD, Hypertension Canada’s 2018 Guidelines for Diagnosis, Risk Assessment, 
Prevention, and Treatment of Hypertension in Adults and Children [12]⁠  changed BP goals 
for patients with CKD to < 140/90 mm Hg, leaving BP target < 130/80 mm Hg for patients 
with diabetes mellitus (DM).  
Results of SPRINT trial may be difficult to extrapolate to general CKD population due to 
exclusion from the trial patients with DM and heart failure and due to the method of BP 
measurement, showing BP values from 5 to 20 mmHg lower, than could be obtained using 
routine methods [5]⁠ . At the same time data about inverse relationship of BP and patients’ 
negative clinical outcomes are accumulating. Concept of so-called J curve was emerged and 
confirmed by several researchers and inverse association with BP was fair only for all-cause 
mortality, but not for incidence of coronary heart disease, ischaemic stroke or ESRD [5] ⁠ . 
Notably, adverse impact of low BP values on the risk of CV death was more prominent, than 
the impact of high BP [5]⁠ . 
The aim of this study is to assess BP control in patients with non-dialysis CKD referred by 
PCPs to the Centre of Nephrology Care. 
 
Material and methods  
This retrospective non-interventional cross-sectional study was conducted in the Centre of 
Nephrology Care in Dnipropetrovsk Mechnikov Regional Hospital, Dnipro, Ukraine. We 
aimed to select patients who are supposed to be followed-up by primary care practitioner 
(PCP), but which due to certain reasons required nephrologist’s consultation. Overall 4540 
patients received medical care in Centre of Nephrology Care in Dnipropetrovsk Mechnikov 
Regional Hospital during 2017. We excluded patients with type 1 DM, polycystic renal 
disease, hereditary renal diseases, operations on kidneys or urinary tract (n = 874) because 
they require multidisciplinary medical approach and are not treated by PCPs. We also 
excluded patients with GFR< 30 ml/min (n = 351) as also requiring cooperation of 
 nephrologist with other specialists due to CKD complications and preparing patients to renal 
replacement therapy. On the next step independent expert excluded 2950 patients as those that 
had no CKD or didn’t require re-examination and could be followed-up in primary care. Thus, 
into the study were enrolled 365 patients with CKD that were followed-up in primary care, 
but required re-examination (including assessment of proteinuria, GFR and BP control) or 
revision of the treatment. All patients were examined and followed-up according to local and 
European standards and gave informed written consent on data collection. The study was 
approved by the Ethics Committee at the Dnipropetrovsk Mechnikov Regional Hospital, 
Dnipro, Ukraine. Study design is shown on Figure 1. 
BP control was assessed according to following standards: KDIGO Clinical Practice 
Guideline for the Management of Blood Pressure in Chronic Kidney Disease [8]⁠  (BP goal ≤ 
140/90 mm Hg or ≤ 130/80 mm Hg < if albumin excretion rate (AER) > 30 mg/24 hours); 
2013 ESH/ECS Guideline for management of HTN [9] ⁠  (BP goal — systolic BP (SBP) < 
140 mm Hg); 2016 European guidelines on CV disease prevention in clinical practice [13] ⁠  
(BP goal < 140/90 mm Hg); 2017 
ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the 
Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults [10]⁠  
(BP goal < 130/80 mm Hg) and Hypertension Canada’s 2018 Guidelines for Diagnosis, Risk 
Assessment, Prevention, and Treatment of Hypertension in Adults and Children [12]⁠  (BP 
goal <140/90 mm Hg or <130/80 mm Hg for patients with DM). HTN was diagnosed in case 
of previously existing diagnosis of HTN or SBP ≥ 140 mm Hg or DBP ≥ 90 mm Hg at the 
moment of admission to the Centre of Nephrology Care. At the moment of data collection 
patients with known HTN were already prescribed antihypertensive treatment. In order to 
examine the effectiveness of treatment regimens (count and classes of drugs) we compared 
these patients to those, who achieved BP goals according to different standards. 
Anaemia was diagnosed if haemoglobin was < 120 g/l in females and < 130 g/l in males. Left 
ventricular hypertrophy (LVH) was diagnosed using Sokolow-Lyon index after 12-lead 
electrocardiography. Proteinuria was diagnosed if urine albumin excretion was > 0.03 g/l or 
protein trace was found in morning urine void. Risk of CKD progression was assessed 
according to KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of 
Chronic Kidney Disease [14] ⁠ . In purpose to classify patients to albuminuria categories we 
 used albumin excretion rate (AER). Body mass index (BMI) was estimated as weight 
(kg)/[height (m)]2. GFR was calculated using GFR-EPI equation [14] ⁠ . 
 
Statistical analysis 
Due to skewness of the data distribution, values were presented as median and interquartile 
range (IQR). Categorical data are presented as n (valid %) to avoid confounding true 
proportion by missing data. Mann-Whitney and Kruskal-Wallis test were used to compare 
continuous data, Chi-square test was used for comparing categorical data. Non-parametric 
Spearman’s correlation coefficient (ρ) was used. In most cases critical value of p was < 0.05. 
In cases of multiple comparisons we used Bonferroni correction and critical value of p 
equalled to 0.05/(number of possible comparisons). Data analysis was performed using Libre 
Office and R. 
 
Results  
Majority of patients were females, but in group of patients with HTN de novo males 
predominated. Nearly 70% of patients had known HTN or HTN de novo. Median age differed 
significantly with distance of more than 10 years, being the highest in patients with known 
HTN. BMI, as well as age, was higher in hypertensive patients, especially in those with 
known HTN. DM, LVH and proteinuria were revealed more often in hypertensive patients, 
while anaemia (non-significantly) — in normotensive ones. Patients with HTN also had 
higher cholesterol levels and lower GFR, but there was no significant difference in CKD 
duration between groups. Normotensive patients had normal median GFR, while in 
hypertensive patients renal function was mildly or moderately decreased. Hypertensive 
patients contributed mainly to high risk groups of CKD progression.  
Clinical characteristics of patients in the study are shown in the Table I. Clinical 
characteristics of patients with preserved renal function depending on presence of proteinuria 
are presented in the Table II. Information about treatment regimens of patients, who achieved 
BP control according to different standards and patients’ characteristics are shown in Table 
III. 
Prevalence of comorbid conditions increased as GFR declined (Fig. 2). Distribution of 
patients with low, moderately high, high and very high risk of CKD progression was the 
 following: patients with stage 1 CKD — 66%, 23%, 1%, 0%; patients with stage 2 CKD — 
69%, 19%, 12%, 0%; patients with stage 3 CKD — 0%, 29.8%, 35.1%, 35.1%. Decline in 
GFR was significantly associated with rise of median age (ρ = –0.56), SBP (ρ = –0.38), DBP 
(ρ = –0.28), BMI (ρ = –0.41), serum uric acid (ρ = –0.44), HTN duration (ρ = –0.36; p < 
0.001 for all correlations) and with AER (ρ = –0.14; p = 0.019). 
Patients with proteinuria had higher prevalence of DM and HTN and more often 
suffered from anaemia and LVH. In both groups patients had comparable age and duration of 
CKD and HTN, but proteinuric patients had more severe course of HTN, assessed by grade of 
HTN (Fig. 3). Non-proteinuric patients achieved BP goals significantly more often, then those 
with proteinuria (Tab. III). Percentage of prescription antiproteinuric drugs such as 
angiotensin converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) 
was 15.3% and 21.2%.  
Females achieved BP targets more often than males and in ACC 2017 group females’ 
proportion was the highest. The lowest frequency of DM was in CCS 2018 group, the highest 
— in ACC 2017 group. We observed in all treated hypertensive patients, as compared to 
patients with controlled BP, higher frequency of LVH, proteinuria, higher median BMI, uric 
acid and lower median GFR. Prevalence of LVH and proteinuria was relatively low in ACC 
2017 and KDIGO 2012 groups. Classes of antihypertensive drugs are ordered in frequency of 
usage. The most widely used classes were rennin-angiotensin-aldosterone system blockers, 
and calcium channel blockers were used in the minority of cases. The most common mode of 
HTN treatment was monotherapy. In patients with controlled HTN, diuretics were used more 
commonly than in the whole cohort of patients receiving HTN treatment. The majority of 
patients with controlled HTN had low risk of CKD progression, regardless of chosen BP 
goals. Continuous values were roughly equal in all groups, but cholesterol level and GFR 
were slightly better in ACC 2017 group. 
 
Discussion 
Our study confirmed that HTN is highly prevalent among patients with CKD in 
ambulatory practice. The most optimal laboratory results and the lowest median age were 
observed in normotensive patients. This group also showed the highest proportion of low-risk 
patients for CKD progression. Slightly better clinical characteristics of patients with HTN de 
novo as compared to patients with known HTN may be explained by age differences (more 
 than 15 years) and milder course of hypertension (assessed by BP levels and percentage of 
controlled BP). Nearly 50% of patients had proteinuria, and this proportion was even higher 
in hypertensive patients, while it should not exceed 40% according to Bolignano (2017) [4] ⁠ . 
Forty-three percent of patients with known HTN had LVH, but even higher prevalence of 
LVH in hypertensive patients in Ukraine was given by Ragot [15] ⁠ . This data indicate that 
HTN in Ukrainian patients, and in patients with CKD as well, is diagnosed with delay and BP 
control is not optimal. Hypertensive patients had higher risk of CKD progression and had 
significantly different GFR values, but not AER. We assume that in our cohort, the risk of 
CKD progression was in higher degree influenced by renal function loss. 
Secondly, patients in our study differed from populations reported in other studies in 
several ways. Overall females’ proportion in our study was slightly higher (Tab. I), while in 
meta-analysis of Mahmoodi et al. (2017) males were more prevalent in CKD populations 
[1]⁠ . At the same time, males predominated among patients with HTN de novo. Median age 
of males and females in our study was 37 (24; 50) years and 52.5 (33; 63) years, respectively. 
The fact that males in our study were younger, than females may be explained by elevated 
alertness concerning evaluation of CV diseases in Ukrainian men. According to ESC: 
Cardiovascular Disease Statistics 2017 Ukrainian population (especially males) is at 
extremely high risk of mortality from CV disease complications [16]⁠ . Prevalence of DM 
among hypertensive patients was much higher, than in other groups (Tab. I), and than in 
official statistics [16, 17] ⁠ . Prevalence of DM among general Ukrainian population is less 
than 3–4% [16, 17] ⁠ , but nearly 18% in patients with hypertension [15]⁠ . According to the 
data from National Registry of patients with CKD (2016) prevalence of diabetic nephropathy 
among patients with CKD was 24% for Ukraine and 23.2% for Dnipropetrovsk region. But 
patients with type 2 DM (which were included to our study) contributed only to 9.2% and 
2.8% of patients for Ukraine and Dnipropetrovsk region respectively [18] ⁠ .  
Next, we have found close interrelations between HTN, loss of renal function and 
proteinuria. Patients in our study showed deterioration of laboratory and instrumental findings 
and raise of comorbidity along with advance of CKD stage (Fig. 2) and these findings do not 
contradict existing concept of CKD progression [3] ⁠ . In other study of Ukrainian patients 
with stage 4–5 CKD normal BP was observed only in 10% of patients, LVH — in 90% and 
more than half of patients had BMI more than 30 kg/m2 [19] ⁠ . Interestingly, decline of renal 
function is associated more strongly with CV risk factors than with AER. Severity of renal 
 function loss is significantly associated with duration of HTN, but not duration of CKD, and 
hypertensive patients seem to be that phenotype of CKD patients, prone to CKD progression. 
On average, proteinuric patients had preserved renal function (GFR > 60 ml/min) and more 
than ¾ of proteinuric patients had HTN (Tab. II). Non-proteinuric patients had the same age, 
duration of CKD and HTN and gender composition, but they had ~15% significantly lower 
prevalence of HTN and significantly higher median GFR. Non-proteinuric patients had higher 
frequency of controlled BP. These data point out strong association of HTN, proteinuria and 
renal function loss and partially correspond with Bolignano’s review [4] ⁠ : we agree that 
HTN is responsible for GFR lowering, but we find no data that absence of proteinuria elevates 
risk of CKD progression. According to CKD-ROUTE study patients with normal-range 
proteinuria are not in higher risk of renal function loss as compared to non-proteinuric 
patients [20]⁠ .  
And, finally, there are several findings concerning antihypertensive treatment and 
achieving BP targets. Proportions of drug types in all treated patients and in patients who 
achieved BP targets were roughly equal (Tab. IV). Beta-blockers were used slightly more 
often in controlled patients while these drugs are supposed to be used in specific 
comorbidities (heart failure, coronary artery disease, atrial fibrillation etc. [8, 21] ⁠ ). CCB, 
that should be included into initial combination of antihypertensive drugs were used scarcely. 
The same pattern as in proportion of types of drugs was observed in number of used drugs. 
First of all, it may indicate on inadequate choice of dosage. The most common regimen was 
monotherapy (60–80%), even higher in well-controlled patients (Tab. IV), while guidelines 
state, that CKD patients usually require combination of antihypertensive drugs [8–10, 12, 13, 
21] ⁠ . Overall effectiveness of monotherapy in our study did not exceed 25% and we suggest 
that wider usage of combined therapy will allow reaching BP targets in higher percent of 
patients. Important question is whether it should start from combination, or drugs should be 
added in step-wise manner, because it may influence frequency of drug-related side-effects as 
well as symptoms related to hypotension [22, 23]⁠ .  
Females achieved BP goals more often, regardless of chosen standard, which may be 
related to higher adherence to antihypertensive treatment [24] ⁠ . Patients who achieved BP 
goals had the similar age, BMI, CKD and HTN duration, and DM prevalence as the whole 
cohort of hypertensive patients. Although overall proportion of controlled BP was low (34% 
and less), it wasn’t much lower, than in reported data [2] ⁠ . Worth mentioning is the fact that 
 approximately 70% of our patients received ACEi of ARB and it is rather similar to reports 
form primary care practitioners in USA [2] ⁠ , but low percentage of renin-angiotensin-
aldosterone blockers in patients with proteinuria (Tab. II) is troublesome. Notable, diuretics, 
that were used scarcely showed good effectiveness and their usage was more often in patients 
with controlled BP. 
It is evident that achieving BP goals is beneficial, as patients with controlled HTN had 
better laboratory and instrumental findings (except of anaemia in ACC 2017 group). But it is 
still questionable whether achieving BP control allows improvement of patients’ 
characteristics, and, thus, their estimated risks, or such a low intensity of antihypertensive 
treatment allows achieving BP goals only in relatively healthy subjects.  
Patients who achieved BP levels of < 130/80 mm Hg are prominent in following 
aspects:  
— they had the most favourable laboratory parameters and low rates of LVH and 
proteinuria (albeit they had higher proportion of anaemia and DM);  
— usage of beta-blockers and diuretics in this group of patients was the most common; 
— antihypertensive therapy in this group was the most intensive;  
— this group had the highest proportion of patients with low risk of CKD progression. 
Non-beneficial, as compared with other groups age and duration of HTN and CKD allow us 
to suggest that these patients were in the same conditions with others. Kovesdy (2017) finds 
doubtful extrapolation of SPRINT trial results on general CKD population, mainly due to 
exclusion of patients with DM and heart failure from the trial [5] ⁠ . Taking into account that 
30% of patients in the group of strict control had DM, it is possible that achieving lower BP 
goals will result in better CV and CKD deterioration prognosis. But here we should also 
mention that usage of threshold of 130/80 mmHg for diagnosis of HTN reclassified 34% of 
normotensive patients with CKD in our study as hypertensive ones. Labelling individual as 
having disease may per se lead to perception of poor health and elevating of BP values 
through different mechanisms [6] ⁠ . 
 
Conclusions 
1. HTN occurs in 70% of patients with CKD and it is controlled in up to 34% cases. 
Usage of ACC 2017 blood pressure targets reclassifies 34% of normotensive patients 
as hypertensive.   
 2. HTN is important factor of CKD progression and it is closely connected with GFR and 
proteinuria. Treatment of proteinuria is crucial in achieving BP goals in patients with 
CKD.  
 
Perspectives 
1. ESC/ESH 2018 guidelines for the management of AH (21) ⁠  recommend BB to be 
used in young females or in patients with specific conditions (such as heart failure, 
atrial fibrillation, coronary artery disease etc.). Patients in our study poorly fit these 
criteria, but in 1/3 of patients BB were used. Influence of BB on proteinuria and CKD 
progression is to be clarified. 
2. According to our data patients with CKD stage 2 have similar risk of CKD progression 
but higher CV risks than patients with CKD stage 1. Differences of CV and CKD 
progression risks in patients with CKD stages 1 and 2 are to be proven on larger 
patients cohorts.  
Limitations 
1. Patients in our study were referred to our centre by primary care practitioners because 
of new symptoms or deterioration and, thus, they do not correspond totally with 
patients with early CKD in ambulatory practice. The fact that 21% of patients in our 
study had HTN de novo confirms this idea. 
2. Gender aspects of CKD progression. In our study males and females had age 
difference of ~15 years that determines difficulties in comparing these groups.  
3. Effects of combinations of first-line antihypertensive drugs weren’t investigated. 
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CKD — chronic kidney disease; HTN — arterial hypertension; KDIGO — Kidney Disease 
Improving Global Outcomes; ESC — European Society of Cardiology; ACC — American 
College of Cardiology; CCS — Canadian Cardiovascular Society 
 
 
 
  
 Table I. Clinical characteristics of patients in the study 
Parameter Total Known 
HTN 
HTN de 
novo 
Normotensive 
 N (valid %) 
Total 365 (100.0) 178 (48.8) 77 (21.0) 110 (30.1) 
Malea,c 155 (42.5) 68 (38.2) 44 (57.1) 43 (39.1) 
Femalea,c 210 (57.5) 110 (61.8) 33 (42.9) 67 (60.9) 
DMb 61 (16.7) 48 (27.0) 12 (15.6) 1 (0.9) 
Anaemia 103 (28.2) 50 (28.1) 14 (18.1) 39 (35.5) 
LVHb,c 77 (21.1) 62 (34.8) 14 (18.2) 1 (0.9) 
Proteinuriab,c 170 (49.6) 90 (52.9) 42 (58.3) 38 (37.6) 
Ris
k of 
CK
D 
pro
gre
ssio
n 
Low 
 
125 (45.0) 51 (34.9) 27 (46.6) 47 (63.5) 
Moderately 
high 
66 (23.7) 39 (26.7) 11 (19.0) 16 (21.6) 
High 54 (19.4) 31 (21.2) 14 (24.1) 9 (12.2) 
Very high 33 (11.9) 25 (17.1) 6 (10.3) 2 (2.7) 
 Median [IQR] 
Age (years)a, b, c 44 [29.5;60] 57 [44.7;66] 40 [31;53] 29.5 [24;38.2] 
BMI [kg/m2] a, b, c 26.1 
[22.2;30.8] 
29.3 
[25.6;32.1] 
26 
[22.7;30.8] 
21.6 
[19.6;24.6] 
CKD duration (years) 5 [1;15.7] 6 [2;15.5] 8 [2;19.5] 4 [1;12] 
HTN duration (years) a, 
b, c 
0 [0;8] 5.5 [0;13] 0 [0;0] 0 [0;0] 
 SBP [mm Hg]a, b, c 130 
[120;150] 
140 
[130;160] 
135 
[122.5;150] 
110 [100;120] 
DBP [mm Hg]b,c 85 [75;95] 90 [80;100] 90 [80;95] 70 [70;80] 
GFR [mL/min]a, b, c 79.3 
[51.5;101.6] 
60.5 
[44.5;86.6] 
80.7 
[58.0;99.2] 
102.2 
[80.5;117.9] 
Uric acid [mcmol/L] 391 
[318;483] 
395 
[314;483] 
369.5 
[321;466] 
411 [316;507] 
Total cholesterol 
[mmol/L] 
5.2 [4.4;5.9] 5.2 [4.5;5.8] 5.7 [4.5;6.6] 4.9 [3.8;6.4] 
AER [mg/24 h] 0 [0;72] 0 [0;72] 0 [0;117] 0 [0;51] 
HTN — arterial hypertension; CKD — chronic kidney disease; DM — diabetes mellitus; 
LVH — left ventricle hypertrophy; BMI — body mass index; SBP — systolic blood pressure; 
DBP — diastolic blood pressure; GFR — glomerular filtration rate; AER — albumin 
excretion rate; a“Known HTN” vs “HTN de novo”; b“Known HTN” vs “Normotensive”; 
c“HTN de novo” and “Normotensive”, p < 0.016 for all comparisons. 
 
Figure 2. Prevalence of comorbidities depending on CKD stage. GFR — glomerular filtration 
rate; DM — diabetes mellitus; LVH — left ventricle hypertrophy; HTN — arterial 
hypertension 
 
 
 Table II. Clinical characteristics of patients depending on presence of proteinuria 
Parameter With proteinuria Without proteinuria P value 
 N (valid %)  
Total 170 (49.5) 173 (50.5)  
Males 71 (41.8) 77 (45.5) 0.60 
Females 99 (58.2) 96 (55.5) 0.60 
DM 33 (19.4) 26 (15.0) 0.28 
Anaemia 63 (37.1) 33 (19.1) < 0.001 
LVH 43 (25.3) 33 (19.9) 0.06 
HTN 132 (77.6) 110 (63.6) 0.004 
Cont
rolle
d 
HT
N 
acco
rdin
g 
to 
guid
eline
s___
_ 
KDIGO 2012  56 (32.9) 26 (72.8) < 0.001 
ESC 2013 78 (45.9) 112 (64.7) 0.02 
ESC 2016 63 (37.1) 99 (52.7) 0.014 
ACC 2017 30 (17.6) 52 (30.1) 0.15 
CCS 2018  
 
59 (34.7) 92 (53.2) 0.045 
ESC grades 
of BP 
Normal 25 (18.9) 36 (32.7)  
Grade 1 HTN 53 (40.2) 49 (44.5)  
Grade 2 HTN 36 (27.3) 18 (16.4)  
Grade 3 HTN 
 
 
18 (13.6) 7 (6.4)  
Class of 
drug 
ACEI 26 (15.3) 32 (18.5) 0.42 
ARB 36 (21.2) 28 (16.2) 0.23 
Diuretics 23 (13.5) 15 (8.7) 0.15 
 Beta-blockers 41 (24.1) 24 (13.9) 0.015 
CCB 24 (14.1) 9 (5.2) 0.005 
 Median [IQR]  
Age (years) 45 [31;59] 45 [28.5;61] 0.89 
BMI [kg/m2] 26.4 [22.6;30.8] 26.0 [22.0;30.8] 0.58 
CKD duration (years)  5 [2;13.2] 6 [1;16.7] 0.58 
HTN duration (years) 0 [0;6.5] 0 [0;9] 0.89 
SBP [mm Hg] 140 [120;150] 130 [110;140] < 0.001 
DBP [mm Hg] 90 [80;100] 80 [75;90] 0.001 
GFR [ml/min] 68.1 [45.6;99.4] 85.4 [62.2;106.4] < 0.001 
Uric acid [mcmol/L) 414 [328;502] 360 [302;440] 0.056 
Total cholesterol [mmol/l] 5.5 [4.8;6.2] 5.1 [4.2;5.7] 0.13 
DM — diabetes mellitus; LVH — left ventricle hypertrophy; HTN — arterial hypertension; 
KDIGO — Kidney Disease Improving Global Outcomes; ESC — European Society of 
Cardiology; ACC — American College of Cardiology; CCS — Canadian Cardiovascular 
Society; ACEI — angiotensin converting enzyme inhibitors; ARB — angiotensin receptor 
blockers; CCB — calcium channel blockers; BMI — body mass index; CKD — chronic 
kidney disease; SBP — systolic blood pressure; DBP — diastolic blood pressure; GFR — 
glomerular filtration rate 
 
 
Figure 3. Age (a), glomerular filtration rate (GFR) (b) and prevalence of proteinuria (c) 
subdivided by gender in all patients in the study. Females were ~15 years older than males (< 
0.001), but had comparable values of GFR and prevalence of proteinuria 
 
 
 
 
 Table III. Clinical characteristics of patients who achieved BP control according to different 
standards 
Parameter  HTN treatment guidelines 
 Known 
HTN 
KDIGO 
2012 
ESC 2013 ESC 2016 ACC 2017 CCS 2018 
 N (valid %) 
Total 178 
(100.0) 
58 (34.1) 54 (30.3) 44 (24.7) 11 (6.2) 37 (20.8) 
Males 68 (38.2) 18 (31.0) 19 (35.2) 16 (36.4) 2 (18.2) 12 (32.4) 
Females 110 (61.8) 40 (69.0) 35 (64.8) 28 (63.6) 9 (81.8) 25 (67.6) 
DM 48 (27.0) 13 (22.4) 13 (24.1) 10 (22.7) 3 (27.3) 3 (8.1) 
Anaemia 50 (28.1) 13 (22.4) 12 (22.2) 11 (25.0) 4 (36.4) 9 (24.3) 
LVH 62 (43.1) 13 (29.5) 16 (38.1) 14 (42.4) 2 (28.6) 9 (33.3) 
Proteinuria 90 (52.9) 11 (19.0) 19 (36.5) 16 (38.1) 2 (20.0) 13 (37.1) 
 Clas
s of 
drug 
ACEI 56 (31.5) 19 (32.8) 20 (37.0) 15 (34.1) 4 (36.4) 13 (35.1) 
ARB 66 (37.1) 22 (37.9) 19 (35.2) 17 (38.6) 3 (27.3) 14 (37.8) 
Beta-
blockers 
66 (37.1) 14 (24.1) 12 (22.2) 11 (25.0) 4 (36.4) 8 (21.6) 
Diuretics 37 (20.8) 14 (24.1) 13 (24.1) 12 (27.3) 4 (36.4) 9 (24.3) 
CCB 36 (20.2) 6 (10.3) 6 (11.1) 5 (11.4) 1 (9.1) 4 (10.8) 
Num
ber 
of 
drug
s 
1 113 (63.5) 44 (75.9) 43 (79.6) 33 (75.0) 7 (63.6) 28 (75.7) 
2 48 (27.0) 12 (20.7) 7 (13.0) 7 (15.9) 3 (27.3) 7 (18.9) 
3 16 (9.0) 1 (1.7) 3 (5.6) 3 (6.8) 1 (9.1) 2 (5.4) 
4 1 (0.6) 1 (1.7) 1 (1.9) 1 (2.3) 0 (0.0) 0 (0.0) 
Risk 
of 
CK
D 
prog
ressi
on 
Low 51 (34.9) 21 (41.2) 21 (44.7) 14 (37.8) 5 (55.6) 11 (36.7) 
Moderate 39 (26.7) 14 (27.5) 10 (21.3) 7 (18.9) 0 (0.0) 6 (20.0) 
High 31 (21.2) 13 (25.5) 13 (27.7) 13 (35.1) 3 (33.3) 10 (33.3) 
Very high 25 (17.1) 3 (5.9) 3 (6.4) 3 (8.1) 1 (11.1) 3 (10.0) 
  Median [IQR] 
Age (years) 57 
[44.7;66] 
60 
[43.7;65.2] 
57.5 
[42.2;65.2] 
58.5 
[40.7;66] 
58 [40;63] 52 
[36.5;64.5] 
BMI [kg/m2] 29.3 
[25.6;32.1] 
28.3 
[24.4;31.7] 
27.2 
[23.7;30.8] 
27.0 
[22.5;30.8] 
27.0 
[23.7;31.2] 
26.7 
[22.3;30.2] 
CKD duration 
(years) 
6 [2;15.5] 10 [2.5;14] 6 [2;12.2] 6 [2;12.7] 11 [4;22] 6 [2.5;13] 
HTN duration 
(years) 
5.5 [0;13] 4 [0;14] 5 [0;16] 4 [0;15.5] 6 [0;16] 4 [0;13.5] 
GFR [mL/min] 60.5 67.0 74.3 70.5 74.2 72.9 
 [44.5;86.6] [48.4;91.8] [48.1;92.1] [43.4;91.5] [41.3;92.5] [44.8;94.7] 
Uric acid 
[mcmol/L] 
395 
[314;483] 
369.5 
[296;416] 
369.5 
[304;464] 
379 
[302;483] 
379 
[251;446] 
357 
[297;407] 
Total cholesterol 
[mmol/L] 
5.2 
[4.5;5.8] 
5.5 
[4.5;6.0] 
5.4 [4.7;5.9] 5.4 
[4.7;5.9] 
4.0 [2.9;–] 5.6 
[4.6;6.1] 
AER [g/24 h] 0 [0;72] 0 [0;0] 0 [0;51] 0 [0;63] 0 [0;22] 0 [0;61] 
HTN — arterial hypertension; ESC — European Society of Cardiology; KDIGO — Kidney 
Disease Improving Global Outcomes; ACC — American College of Cardiology; CCS — 
Canadian Cardiovascular Society; DM — diabetes mellitus; LVH — left ventricle 
hypertrophy; ACEI — angiotensin converting enzyme inhibitors; ARB — angiotensin 
receptor blockers; CCB — calcium channel blockers; BMI — body mass index; CKD — 
chronic kidney disease; SBP — systolic blood pressure; DBP — diastolic blood pressure; 
GFR — glomerular filtration rate; AER — albumin excretion rate 
